Quest Analytics buys BetterDoctor; Analyst Eric Schmidt to join Allogene Therapeutics; Two-thirds of Americans "very concerned" about cost of health insurance.
Eli Lilly CEO says changes needed in drug pricing system; Kentucky sues Walgreens over opioid epidemic; Teva faces migraine drug setback.
BIO afterparty again sparks controversy; GSK meets goal for two-drug HIV treatment; Mylan receives complete response letter for Advair generic.
Drugmakers not dropping prices on Trump timeline; Azar backs insurance for those with preexisting conditions; Stryker denies interest in Boston Scientific takeover.
FDA puts Sage depression treatment on accelerated timeline; AstraZeneca, Lilly cease Alzheimer's treatment trial; Stryker makes offer for Boston Scientific.
Eckert returns to lead Sprout Pharmaceuticals; Sorrell denies prostitution allegation; AHIP warns about removing key Obamacare provisions.
Novo Nordisk considers cutting 3,000 jobs; Pharma companies pressured to move birth control over the counter; Gates Foundation launches a nonprofit biotech.
Bayer closes Monsanto deal after lengthy antitrust review; Bezos, Dimon, Buffett pick CEO to run healthcare venture; Novartis to avoid criminal actions over Cohen payments.
Athenahealth CEO steps down; Former Celgene chief executive wins New Jersey Senate primary; Big Pharma not planning campaign against Trump drug pricing plan.
Medicare Part D brand-name drug costs up even as prescriptions fall; Gottlieb could speed up approval process for competitors of first-to-market drugs; FDA approves Filphila.
Opioid prescriptions drop for fifth year in a row; AstraZeneca reprimanded by U.K. regulator; Samsung partners with Babylon to bring appointments to smartphones.
FDA approves first artificial iris; Trump expects voluntary drug price cuts; Novartis' head of oncology departs.
Allergan to sell women's and infectious disease units; Large clinical trials falling out of favor; American Cancer Society recommends earlier screening for colon cancer.
MIT researchers develop ingestible sensor to detect intestinal bleeding; Diet Madison Avenue goes dark after defamation suit filed; Justice Department report finds Purdue knew about potential for OxyContin abuse.
AstraZeneca lung cancer drug meets key goal; Johnson & Johnson loses another talc lawsuit; Cancer drugs account for 80% of drug sales.
Recro non-opioid injection receives complete response letter from FDA; Pfizer settles False Claims Act allegations; Medtronic reports better-than-expected profit.
Keytruda passes late-stage trial; Astellas to cut 600 jobs in restructuring; Teva expects FDA decision on migraine drug by mid-September.
Geisinger looks to expand DNA sequencing program; Celgene invests $65 million more in Evotec; Oscar launches transparency push.
FDA approves AstraZeneca potassium drug; Nabriva pneumonia treatment meets Phase III endpoints; "Bad Blood" hits bookshelves.
First preventative migraine treatment approved; NIH investigates funding for alcohol study; Trump to block federal funding for abortion clinics.
Biden Cancer Initiative chief gets Transforming Healthcare conference started; Former Novartis CEO on Cohen payments; J&J's Gorsky has advice for Trump on drug pricing plan.
Novartis' top lawyer exits after Cohen payments; More states file suit against Purdue Pharma; J&J to relaunch baby line.
Feds join whistleblower case against Insys; Kleiner Perkins Caufield partner Seidenberg departs; Lilly strikes second acquisition deal in a week.
Beam Therapeutics raises $87 million in Series A funding; Trump drug-pricing plan largely spares big pharma; Novartis regrets Cohen consulting pact.
Trump on drug pricing; Alexa breaks into healthcare; Merck's experimental Ebola vaccine headed to Congo outbreak.
Novartis discloses $1.2 million Cohen payment; FDA calls for two stem cell companies to halt operations; Eli Lilly to buy Armo Biosciences for $1.6 billion
Novartis payments to Trump lawyer made public; Cardinal Health apologizes for mass painkiller shipments; Valeant plans rebranding.
Takeda, Shire reach a deal; Walmart to restrict opioid prescriptions; Glaxo launches global media review.
Elliott makes offer for AthenaHealth; J&J releases data from esketamine late-stage trial; Roche wins fast Tecentriq review from FDA.
Daraprim retains high price tag despite Shkreli sentencing; Merck invests $125 million in Moderna; Cigna posts better-than-expected Q1 earnings.